Actinium Pharmaceuticals, Inc. (ATNWW) financial statements (2021 and earlier)

Company profile

Business Address 275 MADISON AVENUE, 7TH FLOOR
NEW YORK, NY 10016
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments649141721267
Cash and cash equivalents649141721267
Restricted cash and investments00     
Prepaid expense1  0111
Deposits current assets      0
Other undisclosed current assets011010 
Total current assets:6510141822267
Noncurrent Assets
Finance lease, right-of-use asset00
Operating lease, right-of-use asset11
Property, plant and equipment0000000
Restricted cash and investments   0  0
Other undisclosed noncurrent assets00000  
Total noncurrent assets:1210000
TOTAL ASSETS:6612151823278
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:4565412
Other undisclosed accounts payable and accrued liabilities4565412
Debt010  00
Derivative instruments and hedges, liabilities   0037
Due to related parties   0000
Other undisclosed current liabilities0      
Total current liabilities:5565559
Noncurrent Liabilities
Long-term debt and lease obligation  0    
Capital lease obligations0    
Other undisclosed noncurrent liabilities01     
Total noncurrent liabilities:010    
Total liabilities:5665559
Stockholders' equity
Stockholders' equity attributable to parent6169141822(2)
Common stock0000000
Additional paid in capital29221419617715513489
Accumulated deficit(231)(209)(187)(163)(137)(112)(91)
Total stockholders' equity:6169141822(2)
TOTAL LIABILITIES AND EQUITY:6612151823278

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(22)(22)(24)(27)(27)(25)(22)
Operating loss:(22)(22)(24)(27)(27)(25)(22)
Nonoperating income (expense)000034(2)
Interest and debt expense    (0)(0)(0)
Net loss:(22)(22)(24)(27)(24)(21)(25)
Other undisclosed net income attributable to parent    000
Net loss attributable to parent:(22)(22)(24)(27)(24)(21)(25)
Other undisclosed net loss available to common stockholders, basic(0)(0)     
Net loss available to common stockholders, diluted:(22)(22)(24)(27)(24)(21)(25)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(22)(22)(24)(27)(24)(21)(25)
Comprehensive loss, net of tax, attributable to parent:(22)(22)(24)(27)(24)(21)(25)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: